Praxis Moves Away From Depression With Surprising Phase II/III Failure

07 Jun 2022

With GABA-A modulator PRAX-114 missing all endpoints in a monotherapy study, Praxis will cease development of that drug and focus on its candidates for essential tremor and epilepsy.

DEPRESSION miserable depressed , Depression and its consequences, Depressed emotions concept , alone in depression - Image — Praxis moves away from depression after Phase II/III failure

Praxis Precision Medicines, Inc. revealed a surprising Phase II/III failure for major depression disorder (MDD) candidate PRAX-114 but was praised by analysts for moving quickly to re-center its R&D efforts on mid-stage essential tremor and epilepsy programs.

The company announced on 6 June that its GABA-alpha positive allosteric modulator failed to meet the primary endpoint and also...